SUMO3 Modification Accelerates the Aggregation of ALS-Linked SOD1 Mutants

Takako Niikura1*, Yoshiko Kita2*, Yoichiro Abe2

1 Department of Information and Communication Sciences, Faculty of Science and Technology, Sophia University, Tokyo, Japan, 2 Department of Pharmacology, Keio University School of Medicine, Tokyo, Japan

Abstract

Mutations in superoxide dismutase 1 (SOD1) are a major cause of familial amyotrophic lateral sclerosis (ALS), whereby the mutant proteins misfold and aggregate to form intracellular inclusions. We report that both small ubiquitin-like modifier (SUMO) 1 and SUMO2/3 modify ALS-linked SOD1 mutant proteins at lysine 75 in a motoneuronal cell line, the cell type affected in ALS. In these cells, SUMO1 modification occurred on both lysine 75 and lysine 9 of SOD1, and modification of ALS-linked SOD1 mutant proteins by SUMO3, rather than by SUMO1, significantly increased the stability of the proteins and accelerated intracellular aggregate formation. These findings suggest the contribution of sumoylation, particularly by SUMO3, to the protein aggregation process underlying the pathogenesis of ALS.

Introduction

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder that causes the selective loss of motor neurons leading to paralysis and ultimately death within 2–5 years. Although most ALS cases are sporadic, approximately 10% of familial ALS cases are inherited in an autosomal dominant manner. Mutations in superoxide dismutase 1 (SOD1) are the second most common cause of familial ALS (FALS) after C9ORF72 [1,2]. SOD1 mutants have been widely used for in vitro and in vivo models to investigate the pathomechanisms of ALS [3,4].

Mice or rats overexpressing FALS-linked SOD1 mutants develop a human ALS-like phenotype that involves motor neuron degeneration. FALS-linked mutant SOD1 proteins misfold and aggregate into intracellular inclusions both in vitro and in vivo [5], and it is generally accepted that the propensity for aggregation is associated with the pathobiology of SOD1 mutants [4–6]. The aggregation of disease-specific proteins is implicated in the pathogenesis of other neurodegenerative disorders, such as amyloid β in Alzheimer’s disease and α-synuclein in Parkinson’s disease. Therefore, elucidating the process of aggregate formation is important for understanding the pathomechanisms of ALS and other neurodegenerative disorders in which pathological intraneuronal inclusions develop.

Sumoylation, a post-translational protein modification, involves the covalent attachment of small ubiquitin-like modifier (SUMO) proteins to target proteins. Although SUMO is typically conjugated to a specific lysine (Lys) residue within the consensus motif ψKxE/D (where ψ is an aliphatic amino acid) in the target protein, sumoylation can occur at Lys residues outside of the consensus, and not all the consensus Lys residues are sumoylated [7]. The mechanism of the conjugation of SUMO to its target protein is similar to that of ubiquitination. Sumoylation requires a cascade with three enzymes, E1 activating, E2 conjugating, and E3 ligase enzymes; however, unlike ubiquitin, at least three SUMO family proteins, SUMO1, -2, and -3, exist [8,9]. SUMO1 only displays 43% sequence identity with SUMO2 and SUMO3, whereas SUMO2 and SUMO3 are 87% identical [10]. SUMO1 and SUMO2/3 serve distinct functions by targeting different proteins [11,12], though some substrates can be modified by both SUMO1 and SUMO2/3. For instance, RanGAP1, α-synuclein, and tau are predominantly modified by SUMO1 and to a lesser extent by SUMO2/3 [13,14]. In addition, SUMO2/3 but not SUMO1 can form polymeric chains [15], and the de-sumoylating enzymes, sentrin/SUMO-specific proteases (SENPs) 3, 5, 6, and 7, preferentially act on SUMO2/3 versus SUMO1 [16]. It is therefore postulated that SUMO1 and SUMO2/3 can cause different functional consequences on the same substrate. Sumoylated proteins have been implicated in the pathogenesis of several neurodegenerative disorders, such as huntingtin in Huntington’s disease, tau and amyloid precursor protein in Alzheimer’s disease, and α-synuclein and DJ-1 in Parkinson’s disease [6,17]. In ALS model mice, C-terminal fragment of excitatory amino acid transporter 2 (EAAT2) cleaved by caspase 3 is modified by SUMO1 and accumulates in spinal cord astrocytes [10]. The astrocytic expression of sumoylated EAAT2 fragment induces...
motoneuronal NSC34 cells

**Results**

SUMO1 modification of SOD1 at both Lys9 and Lys75 in motoneuronal NSC34 cells

To understand the role of sumoylation in the pathobiology of ALS, we used NSC34 cells, a motor neuron cell line [23] that is widely used for studies on the pathomechanisms of ALS. First, we examined whether the SOD1 protein undergoes sumoylation in these cells by cotransferring FLAG-tagged wild-type (wt) or mutant SOD1 with HA-tagged SUMO1 in the presence of myc-tagged Ubc9, a sumoylation E2 conjugase. The FLAG-SOD1 proteins were immunoprecipitated with an anti-FLAG antibody, and the precipitates were subjected to western blotting using an anti-HA antibody to detect HA-SUMO1. Two dominant bands with molecular masses of approximately 38 and 58 kDa, corresponding to the size of putative mono- and di-sumoylated SOD1, respectively, were detected in cells expressing each SOD1 protein (Fig. 1A, Fig. 2A, lanes 1–4, and Fig. S1A, lanes 1 and 2, arrowheads). Minor bands with a higher molecular mass were also detected but were not derivatives of sumoylated SOD1 because the anti-FLAG antibody did not detect these bands in the anti-FLAG (Fig. S1A and B, lane 5) or anti-HA (Fig. S1A and B, lane 8) antibody precipitates, suggesting that sumoylated proteins other than SOD1 were also coimmunoprecipitated with FLAG-SOD1. These observations indicate that all the SOD1 proteins, including wt, FALS mutants, and N19S mutant, were modified by SUMO1 in the NSC34 cells. The degree of sumoylation was higher for the FALS mutants than for the wt and N19S mutant proteins (Fig. 1A, lanes 3–5, and Fig. 2A, lanes 2 and 5) than for the wt (Fig. 1A, lane 2, and Fig. 2A, lane 1) and N19S mutant proteins (Fig. 1A, lane 6, and Fig. 2A, lane 4). The difference in SUMO1-modification between the FALS mutants and wt was not due to a difference in sumoylation E2 conjugase activity because the levels of Ubc9 and global sumoylation of cellular proteins were almost the same in the lysates of cells transfected with the FALS mutants and wt SOD1 (Fig. S1C).

In addition to the FALS-linked mutant SOD1 proteins, N19S-SOD1 was also modified by both SUMO2 and SUMO3 but at a lower degree compared to the FALS-linked SOD1 mutants (Fig. 2A, lanes 8 and 12). We next used the K/R mutants to determine the sumoylation sites in G93R-SOD1. The K75R mutation, but not the K9R mutation, significantly reduced G93R-SOD1 sumoylation by SUMO2 and SUMO3 (Fig. 2B, lanes 3 vs. 2, and 7 vs. 6), indicating that the SUMO2/3 modification of the mutant SOD1 proteins mainly occurs at Lys75.

**SUMO3 increases mutant SOD1 protein aggregation**

We have previously demonstrated that FALS-linked SOD1 mutants are modified by SUMO2 and SUMO3 in CHO cells expressing EGFP-fused SOD1 proteins [24]. Using this system, we then examined the effects of SUMO1 and SUMO3 on the aggregation of FALS-linked mutant SOD1 proteins. First, we observed the subcellular localization of SUMO1 and SUMO3 cotransfected with wt-SOD1-EGFP by immunofluorescent staining using an anti-HA antibody (Fig. 3). As reported previously, SUMO1 and SUMO3 are mainly localized to the nucleus and cytosol, respectively. Regardless of the localization pattern of each SUMO protein, wt SOD1-EGFP was found to be localized throughout the cell body (Fig. 3 arrows). In contrast, FALS-mutant SOD1-EGFP formed aggregates in the perinuclear area (Fig. 3 arrow heads), and a portion of the SUMO protein colocalized with the aggregates. A quantitative analysis (Fig. 4A) showed that the coexpression of SUMO1 and Ubc9 with A4T/G93R-SOD1 slightly, but not significantly, increased the number of aggregate-positive cells, whereas significant increases in
aggregate formation were observed in the cells coexpressing SUMO3, Ubc9, and A4T/G93R-SOD1. These results indicate that SUMO3 has more influence on the aggregate formation of mutant SOD1 than does SUMO1. To examine whether the enhancement of aggregation of G93R-SOD1 by coexpression of SUMO3 is induced by direct SUMO3 modification of the SOD1 protein, we introduced the K/R mutations in the G93R-SOD1-EGFP fusion construct (Fig. 4B). Consistent with Figure 2B, K75R mutant but not K9R mutant significantly reduced the rate of aggregate positive cells, suggesting that SUMO3 modification on Lys75 directly contributes to the aggregate formation of mutant SOD1 proteins.

SUMO3 modification stabilizes FALS-linked SOD1 mutants

We next examined whether sumoylation affects the stability of FALS-linked mutant SOD1 proteins in NSC34 cells (Fig. 5). NSC34 cells expressing G93R-SOD1, SUMO1/3, and Ubc9 were treated with cycloheximide (CHX), a protein synthesis inhibitor, and the expression levels of the G93R-SOD1 protein were analyzed along a time course. The G93R-SOD1 levels similarly decreased during CHX treatment in a time-dependent manner, with or without coexpression of SUMO1 [Fig. 5B, C]. On the other hand, the coexpression of SUMO3 significantly increased the initial G93R-SOD1 levels (Fig. 5A, lane 7, and 5B) compared to that of SUMO1 and, in contrast to the coexpression of SUMO1, maintained the high level of G93R-SOD1 up to 6 h of CHX treatment (Fig. 5A, lanes 8 and 9, and 5B, C). The cells expressing the A4T-SOD1 protein showed results similar to those expressing G93R-SOD1, i.e., SUMO3 itself significantly increased the level of A4T-SOD1 (Fig. S3A, lane 7, and Fig. S3B), and the level of the protein was maintained during 6 h of CHX treatment (Fig. S3A, lanes 8 and 9, and Fig. S3B, C). These results suggest that SUMO3 plays a pivotal role in stabilizing FALS-linked mutant SOD1 proteins. Interestingly, our immunoblotting results with the anti-FLAG antibody exhibited a band with a size of approximately 19 kDa (Fig. S1A, lanes 8 and 9, arrow), corresponding to nonsumoylated SOD1, in the anti-HA antibody immunoprecipitate from the lysate of cells expressing HA-SUMO and G93R-SOD1-FLAG. However, this 19-kDa band was not detectable in
the precipitates from cells expressing HA-SUMO and wt SOD1-FLAG (Fig. S1B, lanes 8 and 9, arrow). Considering the fact that the majority of the SOD1 protein was not sumoylated (Figs S1A and B, lanes 4–6, indicated with an arrow), these results strongly suggest that the SUMO conjugation of mutant SOD1 accelerates the aggregation of the protein, incorporating the nonsumoylated form.

**Discussion**

In this study, we found that Lys75 of mutant SOD1 proteins is modified not only by SUMO1 but also by SUMO2 and SUMO3 (Fig. 2). Fei et al. showed that the SUMO1 modification of SOD1 increases its aggregation and stability [22], and we observed a similar phenomenon, though the effect was not prominent in motoneuronal NSC34 cells. In contrast, SUMO3 modification significantly accelerated intracellular aggregate formation and stabilized the FALS-linked SOD1 mutant proteins (Figs. 4, 5). Although SUMO1 and SUMO2/3 share the same process for
conjugation at Lys residues of target proteins, each SUMO displays a preferential intracellular localization: SUMO1 mainly localizes to the nuclear membrane, and SUMO3 is localized in the cytosol (Fig. 3) [15,25]. Because SOD1 is a cytoplasmic protein, SUMO3 rather than SUMO1 should be more readily accessible to SOD1. In addition, SUMO2 and SUMO3 are found in a free, nonconjugated form in vivo, whereas SUMO1 mainly exists in a conjugated form. SUMO2/3 conjugation is induced by cellular stimuli, such as heat-shock and oxidative stress [14]. Therefore, it is more likely that SOD1 is conjugated by SUMO2/3, rather than by SUMO1, under conditions of stress.

SUMO3 increased the stability of nonsumoylated SOD1 mutant proteins (Fig. 5). This finding raises the question of how SUMO3 increases the total amount of nonsumoylated SOD1 mutant protein. One possibility is that the elevated SUMO3 level induced the global stabilization of proteins via modification of proteasomal degradation system. We observed that the mutation at Lys75, the major sumoylation site of SUMO3, significantly reduced the aggregate formation of mutant SOD1 proteins (Fig. 4B), suggesting that SUMO3 modification directly affects the aggregate formation. Moreover, the nonsumoylated mutant SOD1 proteins coimmunoprecipitated with SUMOs, whereas the nonsumoylated wt SOD1 proteins, which do not form aggregates, were undetectable in the SUMO immunoprecipitates (Fig. S1). Therefore, it appears unlikely that the SUMO3-induced increase in mutant SOD1 aggregation is merely caused by increased levels of SOD1 proteins, though it cannot completely rule out the possibility that SUMO3-target proteins other than SOD1 are involved in aggregate formation of mutant SOD1 proteins. It is rather more likely that the global augmentation of SUMO3 modification increases the amount of sumoylated SOD1 proteins and causes the recruitment of nonsumoylated SOD1 mutant proteins to aggregate.

**Figure 3. SUMOs colocalize with familial ALS-linked SOD1 mutants in intracellular aggregates.** CHO cells were cotransfected with plasmids expressing EGFP-fused SOD1 (either wild-type or mutant), HA-tagged SUMO 1/3, and myc-tagged Ubc9. The cells were fixed after 24 h of transfection and immunostained with anti-HA antibody and DyLight594-conjugated anti-mouse IgG antibody, followed by counterstaining with DAPI. Representative images from two independent experiments are shown. The bar in the upper left panel indicates 10 μm. Arrowheads and arrows indicate cells with and without intracellular SOD1 protein aggregates, respectively. In all triple transfections, all GFP-positive cells were DyLight594 (SUMO)-positive (detail in Supporting Information Table S1).

doi:10.1371/journal.pone.0101080.g003
proteins into the intracellular aggregates formed by sumoylated SOD1 proteins, resulting in accelerated aggregation formation. In addition, it has been reported that mutant SOD1 can form prion-like aggregation and has spreading ability [26]. It is thus speculated that sumoylation may trigger such prion-like characteristics in mutant SOD1. Multiple lines of evidence indicate that SOD1 aggregate formation closely correlates with cytotoxicity in cellular models and decreased survival in model mice [1,18–21,23]. Taken together, it is assumed that the sumoylation-induced acceleration of SOD1 aggregation is linked to neurotoxicity in ALS pathogenesis.

We also demonstrated that SOD1 can be modified by SUMO1 at two sites, Lys9 and Lys75, in motoneuronal NSC34 cells (Fig. 1). Both Lys9 and Lys75 are located within a canonical consensus sequence for sumoylation, ψKx/E/D (where ψ is an aliphatic amino acid): LKGD and PKDE, respectively. SUMO1 modification at Lys75, but not Lys9, was previously demonstrated by an in vitro assay using purified proteins [22]. However, the additional observed sumoylation at Lys9 is most likely because of the difference between the assay systems, i.e., in vitro versus in vivo. Consistent with our findings, proteomic analyses have demonstrated SOD1 sumoylation at multiple sites in a yeast system [27,28].

**Figure 4. SUMO3 modification increases the aggregation of SOD1 proteins.** CHO cells were cotransfected with plasmids expressing EGFP-fused SOD1 (either wild-type or mutant), HA-tagged SUMO1/3, and myc-tagged Ubc9 and fixed after 24 h of transfection. Images of randomly selected fields in each well were recorded, and the number of cells with and without aggregates were counted. The total number of GFP-positive cells counted in each sample (mean ± SD) were 185±49 (A) and 338±124 (B). A. SUMO3 increased aggregate formation of mutant SOD1 proteins. The percentages of aggregate-positive cells (mean and SD) were plotted (triplicate sample). Statistically significant differences (p<0.05) between with and without SUMO3 were analyzed by t-test and indicated by asterisks. B. K75R mutation significantly reduced the aggregate formation of G93R-SOD1. The percentages of aggregate-positive cells (mean and SD) were plotted (sextuplicate samples). Statistically significant difference (p<0.05) by a one-way ANOVA followed by a post-hoc test is indicated by asterisks. N.S. indicates not significant. doi:10.1371/journal.pone.0101080.g004

**Figure 5. A familial ALS-linked SOD1 mutant is stabilized by SUMO3 modification.** NSC34 cells were cotransfected with plasmids expressing FLAG-tagged G93R-SOD1, HA-tagged SUMO1, SUMO3, or the empty vector (vec), and myc-tagged Ubc9. After 16 h of transfection, the cells were treated with 50 μg/ml cycloheximide for 3 or 6 h or left untreated (time 0). The cell lysates were subjected to an immunoblot analysis with anti-FLAG antibody (A upper panel) and anti-β-actin antibody (A lower panel). A. A representative immunoblot result is shown. B. Quantitative analysis of the immunoblot. The intensity of each band was quantified using ImageJ and normalized to the arbitrary units of β-actin, and the means and SD (n=4) were calculated. * indicates a statistically significant difference (p<0.05) among the three transfection conditions (vec, SUMO1, SUMO3) at time 0. Statistically significant differences (p<0.01) between time 0 of each condition are indicated by *. N.S. indicates not significant. C. Quantitative analysis of the immunoblot. The data in B are expressed relative to the 0 h value (=1). doi:10.1371/journal.pone.0101080.g005
observed in the lysate of cells transfected with G93R/K9R/K75R-SOD1 triple mutant and SUMO1 (Fig. 1B, lane 4), suggesting the existence of minor sumoylation sites other than Lys9 and Lys75 in human SOD1.

Oxidative stress results from an imbalance in the production and removal of reactive oxygen species. Because free radical production increases with aging, oxidative stress is a risk factor for the onset of aging-related neurodegenerative disorders, including ALS [29]. Indeed, elevated oxidative damage in proteins is observed in sporadic ALS patients [30,31] and in an ALS model of SOD1 transgenic mice [32]. SUMO2/3 conjugation is a major response to oxidative stress [8,33,34], and global protein modification by SUMO2/3 is increased by hydrogen peroxide treatment in yeast [14] and HeLa cells [35], supporting the link between oxidative damage and SUMO2/3 protein modification. A cellular model of ischemia induced by oxygen and glucose deprivation also increases global protein modification by SUMO2/3. The stress-induced SUMO2/3 modification in this model appears to function as a neuroprotective mechanism because the knockdown of SUMO2/3 increases cellular vulnerability to ischemic stress [36,37]. Thus, it is unclear whether oxidative stress-induced sumoylation is neurotoxic or neuroprotective. Nevertheless, we propose that the stress-induced elevation of global sumoylation accelerates the aggregation of mutant SOD1 proteins and consequently activates cytopathic pathways in motor neurons.

DNA-binding protein 43 (TDP-43) has been identified as a major aggregating protein in ALS and frontotemporal lobar degeneration [38], and TDP-43-positive aggregates are found in most sporadic cases and in familial cases caused by its mutation [39]. TDP-43 has a canonical sumoylation motif at positions 135–138, colocalizes with SUMO2/3 in intracellular inclusions, and is directly sumoylated in insoluble cellular protein fractions [40]. Additionally, heat-shock induces the accumulation of SUMO2-conjugated TDP-43 by 7-fold [41]. These findings suggest that SUMO2/3 is involved in TDP-43 aggregation under stress conditions. Considering our results, we propose that stress-induced SUMO2/3 modification plays an important role in the aggregate formation of ALS-associated proteins, which contributes to the pathogenesis of ALS.

Materials and Methods

Plasmids

Plasmids containing wt, FALS-linked SOD1 mutants (G93R, G85R, and A4T), and N19S-SOD1 cDNA were previously described [24]. K9R and K75R mutations were introduced via site-directed mutagenesis using the primers 5'-GTTGCGGCTGCTAGGGGCAGCGCCGAC-3' (K9R sense), 5'-CTGGGCGCTGCGCCGCTAGACACGCGCAC-3' (K9R antisense), 5'-CAGCCTGCGGGCGCAGGATGAGCAGG-3' (K75R sense), and 5'-GCCCTCTCTTAGCTCCCTTTGCCACGGACAC-3' (K75R antisense). The pXJ-HA-SUMO1 and pXJ-myc-Ubc9 plasmids were provided by Dr. Victor Yu (National University of Singapore, Singapore). The SUMO2 and SUMO3 cDNAs were cloned by reverse-transcription PCR from the human brain cDNA library using the primers 5'-GATCATGCGCGCCGACGAAACCCCAAG-3' (SUMO2 sense), 5'-CCCGGTAGCTGACGACCTCCCTGCTG-3' (SUMO2 antisense), 5'-GATCATGCGCGCCGACGAAACCCCAAG-3' (SUMO3 sense), and 5'-CCCCGGGCTGAAAATGCGCCGGACACG-3' (SUMO3 antisense); the products were inserted into the pXJ-HA vector.

Cell culture, transfection, and immunoprecipitation

HEK293 and NSC34 cells, the hybrid cells of motor neuron-enriched embryonic mouse spinal cord cell with motor neuron- blastsoma N18TG2[23], were cultured in Dulbecco’s modified Eagle’s medium (D-MEM) supplemented with 10% fetal bovine serum (FBS), 50 units/ml of penicillin, and 50 μg/ml of streptomycin (Invitrogen, Carlsbad, CA, USA). HEK293 (7×10^5 cells/dish) and NSC34 cells (5×10^5 cells/dish) were seeded into 60-mm dishes and transfected with plasmids expressing FLAG-tagged SOD1 (wt or mutant), HA-tagged SUMO1/2/3, and myc-tagged Ubc9 by lipofection (Lipofectamine with Plus reagent, Invitrogen). To prepare the transfection mixture, the plasmid DNAs were mixed in a ratio of 2:1:1 for SOD1:SUMO:Ubc9. After 24 h, the cells were harvested and lysed in RIPA buffer (10 mM sodium phosphate [pH 7.2], 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1% sodium deoxycholate, 10 mM N-ethylmaleimide, and protease inhibitors [Complete protease inhibitor cocktail, Roche Diagnostics, Indianapolis, IN, USA]. The cell debris was removed by centrifugation (16,000×g, 20 min, 4°C), and the clarified cell lysates (500 μg of protein) were subjected to immunoprecipitation using anti-FLAG M2 antibody-conjugated beads (Sigma, St. Louis, MO, USA).

Immunoblot analysis

Immunoprecipitated samples were subjected to SDS-PAGE, followed by transfer to polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA). The membranes were blocked with 10% skim milk in TBS-T (20 mM Tris-HCl [pH 7.6], 136 mM NaCl, and 0.1% Tween 20) and incubated with rabbit anti-SOD1 antibody (1:1000, Sigma, St. Louis, MO, USA). The primary antibodies used were HRP-conjugated anti-HA (Roche), HRP-conjugated anti-FLAG (Sigma), and HRP-conjugated anti-actin (Sigma) antibodies.

Protein stability analysis

NSC34 cells (1.5×10^5 cells/well) were seeded into 12-well plates and transfected with one of the plasmids expressing FLAG-tagged AFT-SOD1, HA-tagged SUMO 1/3, or the empty vector and myc-tagged Ubc9 using lipofection. After 16 h of transfection, the cells were treated with 50 μg/ml cycloheximide (CHX) for 3 or 6 h and lysed in T-PER lysis buffer (Thermo Scientific) and cotransfected with plasmids expressing enhanced green fluorescent protein (EGFP)-fused SOD1 (wt or mutant), HA-tagged SUMO1/3, and myc-tagged Ubc9 by lipofection. To prepare the transfection mixture, the plasmid DNAs were mixed in a ratio of 2:1:1 for SOD1:SUMO1/3:Ubc9. After 24 h of transfection, the cells were mixed in a ratio of 2:1:1 for SOD1:SUMO1/3:Ubc9. After 24 h of transfection, the cells were mixed in a ratio of 2:1:1 for SOD1:SUMO1/3:Ubc9. After 24 h of transfection, the cells were fixed with 4% paraformaldehyde in PBS and incubated with blocking solution (5% bovine serum albumin in PBS), anti-HA antibody (M180-3, MBL, Nagoya, Japan), and DyLight594-conjugated anti-mouse IgG antibody.
Quantification of SOD1 aggregates
CHO cells (1x10^5 cells/well) were seeded into 6-well plates and cotransfected with plasmids expressing EGFP-fused SOD1 (wt or mutant), HA-tagged SUMO1/3, and myc-tagged Ubc9 by lipofection. After 24 hours, the cells were fixed with 4% paraformaldehyde in PBS, and EGFP fluorescence was detected using a fluorescence microscope (Olympus). Images of randomly selected fields in each well were recorded. We counted cells containing heterologous accumulation of fluorescence with high intensity as aggregate-positive cells (indicated with arrowheads in Fig. 3), and the percentages of aggregate-positive cells were calculated.

Statistical analysis
All statistical analyses were performed using Prism5 (Graph Pad Software, La Jolla, CA, USA). Two group comparison was analyzed by t-test. Group differences were analyzed by a one-way ANOVA, followed by post-hoc tests (Tukey’s multiple comparison test). The results expressed as mean ± SD.

Supporting Information
Figure S1 SOD1 proteins are sumoylated by SUMO1 and SUMO3. NSC34 cells were cotransfected with plasmids expressing FLAG-tagged G93R (A) or wild-type (B) SOD1, HA-tagged SUMO1/3 or vector, and myc-tagged Ubc9. The cell lysates were immunoprecipitated with anti-FLAG M2 antibody or anti-HA antibody (M180-3, MBL). Immunoprecipitates (A, B) and input samples (15 μg protein) (C) were analyzed by immunoblotting with HRP-conjugated anti-HA, anti-FLAG, anti-myc, and anti-β-actin antibodies. In D, immunoprecipitate of anti-FLAG antibody from NSC34 cells expressing G93R-SOD1-FLAG, HA-SUMO3, and myc-Ubc9 (indicated as IP) and the lysate of HEK293 cells (15 μg protein) expressing G93R-SOD1-FLAG, HA-SUMO3, and myc-Ubc9 were analyzed side-by-side. Arrowheads indicate the bands commonly detected in immunoprecipitates of anti-FLAG and anti-HA antibodies, suggesting that these bands are sumoylated SOD1 proteins. Arrows indicate the bands of non-sumoylated SOD1 monomer. Non-sumoylated G93R-SOD1 but not wt SOD1 monomer was detected in immunoprecipitates of anti-HA antibody. Asterisks indicate the bands detected by anti-FLAG antibody in immunoprecipitates of anti-FLAG antibody and HEK293 lysate, but not in immunoprecipitate of anti-HA antibody, suggesting that these bands are nonsumoylated SOD1 dimers.

Figure S2 Ubc9 promotes sumoylation of SOD1. NSC34 cells were cotransfected with plasmids expressing FLAG-tagged mutant SOD1, HA-tagged SUMO1/3, and either myc-tagged Ubc9 or the empty vector. The presence (+) or absence (−) of Ubc9 is indicated above the lane. The cell lysates were immunoprecipitated with an anti-FLAG M2 antibody. Input samples (15 μg protein) (A) and immunoprecipitates (B) were analyzed by immunoblot with HRP-conjugated anti-HA, anti-FLAG, anti-myc, and anti-β-actin antibodies. The global sumoylation of cellular proteins was significantly increased in the presence of Ubc9 (A upper panel). Consistently, the amount of sumoylated SOD1 proteins was markedly increased in the presence of Ubc9 (B upper panel).

Figure S3 A. Familial ALS-linked SOD1 mutant is stabilized by SUMO3 modification. NSC34 cells were cotransfected with plasmids expressing FLAG-tagged A4T-SOD1, one of the HA-tagged SUMO1, SUMO3, or the empty vector, and myc-tagged Ubc9. After 16 h of transfection, the cells were treated with 50 μg/ml cycloheximide for 3 or 6 h or untreated (time 0). The cell lysates were subjected to an immunoblot analysis with anti-FLAG antibody (A upper panel) and anti-β-actin antibody (A lower panel). A representative immunoblot result is shown. B. Quantitative analysis of the immunoblot. The intensity of each band was quantified by using ImageJ and normalized to the arbitrary units of β-actin, and the means and SD (n = 3) were calculated. C. Quantitative analysis of the immunoblot. The data in B are expressed relative to the 0 h value (= 1). Statistical analysis between 0 h and 6 h was performed by t-test and the p values are shown. The amount of SOD1 protein decreased over time in the presence of SUMO1. On the other hand, the amount of SOD1 proteins did not show an apparent difference among treatment time in the presence of SUMO3.

Table S1 Coexpression of SOD1 and SUMO in CHO cells. Transfection efficiency of SOD1 and SUMO in CHO cells is summarized (representative data of two independent experiments). Immunostained cells used in Figure 3 were counted. The numbers of DAPI-positive nuclei were used as total cell numbers. All GFP-positive cells were also DyLight-positive, indicating that SOD1 and SUMO were coexpressed in these cells.

Author Contributions
Conceived and designed the experiments: TN YA. Performed the experiments: TN YK. Analyzed the data: TN YA. Contributed reagents/materials/analysis tools: TN YK YA. Contributed to the writing of the manuscript: TN YA.

References
1. Renton AE, Chio A, Traynor BJ (2014) State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 17: 17–23.
2. Svedhara J, Brown RH Jr (2013) Amyotrophic lateral sclerosis: Problems and prospects. Ann Neurol 74: 309–316.
3. Ilieva H, Polyomenidou M, Cleveland DW (2009) Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol 187: 761–772.
4. Beno-Abreu A, Van Damme P, Van Den Bosch L, Roberrecht W (2010) The neurobiology of amyotrophic lateral sclerosis. Eur J Neurosci 31: 2247–2263.
5. Shaw BF, Valentine JS (2007) SUMO on the road to neurodegeneration. Biochim Biophys Acta 1773: 694–706.
6. Dorval V, Fraser PE (2007) SUMO on the road to neurodegeneration. Biochim Biophys Acta 1773: 694–706.
7. Pfefferke GJ, Hofmann K, Dohmen RJ (2012) SUMO playing tag with ubiquitin. Trends Biochem Sci 37: 23–31.
8. Malchior F (2000) SUMO—nonclassical ubiquitin. Annu Rev Cell Dev Biol 16: 591–626.
9. Rouas-Acosta G, Russell WK, Deyrieux A, Russell DH, Wilson VG (2005) A universal strategy for proteomic studies of SUMO and other ubiquitin-like modifiers. Mol Cell Proteomics 4: 56–72.
10. Petrioli PG, Naught B, Zhang XJ, Rogers R, Aitchison J, et al. (2006) Automated identification of SUMOylation sites using mass spectrometry and SUMOOno pattern recognition software. Nat Methods 3: 535–539.
11. Dorval V, Fraser PE (2006) Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein. J Biol Chem 281: 9919–9924.
14. Saitoh H, Hincheny J (2000) Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. J Biol Chem 275: 6252–6258.
15. Woo CH, Abe J (2010) SUMO–a post-translational modification with therapeutic potential? Curr Opin Pharmacol 10: 146–155.
16. Hay RT (2007) SUMO-specific proteases: a twist in the tail. Trends Cell Biol 17: 370–376.
17. Sarge KD, Park-Sarge OK (2011) SUMO and its role in human diseases. Int Rev Cell Mol Biol 298: 167–183.
18. Ghibli SL, Bostom-Hoves W, Lavina ZS, Gustincich S, Brown RH Jr, et al. (2007) A caspase-3-cleaved fragment of the glial glutamate transporter EAAT2 is sumoylated and targeted to promyelocytic leukemia nuclear bodies in mutant SOD1-linked amyotrophic lateral sclerosis. J Biol Chem 282: 32480–32490.
19. Foran E, Bogish A, Griffoh M, Roncagl A, Gustincich S, et al. (2011) Motor neuron impairment mediated by a sumoylated fragment of the glial glutamate transporter EAAT2. Glia 59: 1719–1731.
20. Wang Z, Wang R, Sheng H, Sheng SP, Paschen W, et al. (2013) Transient ischemia induces massive nuclear accumulation of SUMO2/3-conjugated proteins in spinal cord neurons. Spinal Cord 51: 139–143.
21. Fei E, Jia N, Yan M, Ying Z, Sun Q, et al. (2006) SUMO-1 modification increases human SOD1 stability and aggregation. Biochem Biophys Res Commun 347: 406–412.
22. Cashman NR, Durham HD, Blusztajn JK, Oda K, Tabira T, et al. (1992) Neuroblastoma x spinal cord (NSC) hybrid cell lines resemble developing motor neurons. Dev Dyn 194: 209–221.
23. Ohtani T, Kanekura K, Hashimoto Y, Kawasaki M, et al. (2005) Expression of N19S–SOD1, an SOD1 mutant found in sporadic amyotrophic lateral sclerosis patients, induces low-grade motoneuronal toxicity. J Neurosci Res 81: 720–729.
24. So HL, Li SS (2002) Molecular features of human ubiquitin-like SUMO genes and their encoded proteins. Gene 296: 65–73.
25. Ling SC, Polymenidou M, Cleveland DW (2013) Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron 79: 416–430.
26. Zhou W, Ryan JJ, Zhou H (2004) Global analyses of sumoylated proteins in Saccharomyces cerevisiae. Induction of protein sumoylation by cellular stresses. J Biol Chem 279: 32626–32628.
27. Wykoff DD, O’Shea EK (2005) Identification of sumoylated proteins by systematic immunoprecipitation of the budding yeast proteome. Mol Cell Proteomics 4: 73–83.
28. Nakamura T, Cho DH, Lipton SA (2012) Redox regulation of protein misfolding, mitochondrial dysfunction, synaptic damage, and cell death in neurodegenerative diseases. Exp Neurol 238: 12–21.
29. Shaw PJ, Ince PG, Falouk G, Manu D (1995) Oxidative damage to protein in sporadic motor neuron disease spinal cord. Ann Neurol 38: 691–693.
30. Hay RT, Abe J, Yamazaki K, Murata T, Ishizaki E, et al. (1999) Increase in oxidized NO products and reduction in oxidized glutathione in cerebrospinal fluid from patients with sporadic form of amyotrophic lateral sclerosis. Neurosci Let 260: 204–206.
31. Liu D, Wen J, Liu J, Li L (1999) The roles of free radicals in amyotrophic lateral sclerosis: reactive oxygen species and elevated oxidation of protein, DNA, and membrane phospholipids. Free J 13: 2318–2328.
32. Tempe D, Pichaceck M, Bossi (2008) SUMO under stress. Biochem Soc Trans 36: 874–876.
33. Parakh S, Spencer DM, Halloran MA, Soo KY and Atkin JD (2013) Redox regulation in amyotrophic lateral sclerosis. Oxid Med Cell Longev 2013: 408681.
34. Huang C, Han Y, Wang Y, Sun X, Yan S, et al. (2009) SENP3 is responsible for HIP1 transactivation under mild oxidative stress via p300 de-SUMOylation. Embo J 28: 2748–2762.
35. Cimarosti H, Ashikaga E, Jallari N, Dearden L, Rubin P, et al. (2012) Enhanced SUMOylation and SENP-1 protein levels following oxygen and glucose deprivation in neurons. J Cereb Blood Flow Metab 32: 17–22.
36. Datwyler AL, Lattig-Tumennann G, Yang W, Paschen W, Lee SL, et al. (2011) SUMO2/3 conjugation is an endogenous neuronal protective mechanism. J Cereb Blood Flow Metab 31: 2152–2169.
37. Neumann M, Sampathu DM, Kwong LK, Trax AC, Micsenyi MC, et al. (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314: 130–133.
38. Van Deerlin VM, Leverenz JB, Berek LM, Bird TD, Yuan W, et al. (2008) TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol 7: 409–416.
39. Seyfried NT, Goual ZM, Dammer EB, Xia Q, Duong DM, et al. (2010) Multiplex SILAC analysis of a cellular TDP-43 proteinopathy model reveals protein inclusions associated with SUMOylation and diverse polyubiquitin chains. Mol Cell Proteomics 9: 705–718.
40. Goebelowski F, Matic I, Tarham MH, Cole C, Yin Y, et al. (2009) System-wide changes to SUMO modifications in response to heat shock. Sci Signal 2: ra24.